CCA EDUCATE

CHOLANGIOCARCINOMA AUSTRALASIA

COMPILED BY
Steve Holmes
Email: Steve

Ph: +61415153522
FB Messenger
FB Page Steveholmes

RESEARCH | MUTATIONS | TREATMENT | SURGERY
Please help us to

EQUIP: the Newly Diagnosed Patient with a Cancer Tool Kit immediately after diagnosis.

EMPOWER: the Newly Diagnosed Patient and Caregivers with today's lifesaving information, TODAY!

CONNECT: the Newly Diagnosed Patients and Caregivers to our Global Community

Help by sharing this link

We need your help and feedback

    Please help us improve our content and delivery

    Rate this page...


    Easy to followHard To followHelpedDid not help

    Are you a . . .


    PatientCaregiverFamily/FriendDoctorNurseOther

    How can we improve this?


    TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival

    • WHAT: IDHI Mutations
    • WHY: Breakthrough
    • HOW: Trial Success

    1DH1 and TIBSOVO® (ivosidenib)

    Primary End Point Achieved

    Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients – TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo – “Advanced cholangiocarcinoma is a life-threatening disease with no currently approved treatment options,” said Chris Bowden, M.D., chief medical officer at Agios. “The data from the ClarIDHy Phase 3 trial demonstrate the clinically significant benefit of TIBSOVO® in patients with this challenging disease who harbor the IDH1 mutation.

    View Media Release

    Phase 3 trial sees significant benefit

    “The data from the ClarIDHy Phase 3 trial demonstrate the clinically significant benefit of TIBSOVO® in patients with this challenging disease who harbor the IDH1 mutation. We are committed to working with regulators to bring this potential treatment option to patients as quickly as possible. We thank the patients and physicians who participated in the ClarIDHy study, without whom this important advancement would not be possible.”

    View Media Release

    Patient ToolKits

    Newly Diagnosed?

    7 Must Do Steps
    Cholangiocarcinoma Patient Toolkits @ www.thecancertoolkit.com
    Patient ToolKits